{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:51:38Z","timestamp":1775533898631,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106553","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:59:13Z","timestamp":1775530753000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Disease Control in Disseminated Primary Splenic Leiomyosarcoma Treated With Sequential Gemcitabine\u2013Docetaxel and Pazopanib Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Saida","family":"Kurbanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biloliddin","family":"Sharobiddinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oqila","family":"Abdusattorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravshan","family":"Abdusattorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.11152\/mu-3325","article-title":"Primary splenic leiomyosarcoma - case report and literature review","volume":"24","author":"Ioani\u021bescu ES","year":"2022","unstructured":"Ioani\u021bescu ES, Grasu M, Toma L. Primary splenic leiomyosarcoma - case report and literature review. Med Ultrason. 2022, 24:114-6. 10.11152\/mu-3325","journal-title":"Med Ultrason"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-5-135","article-title":"Locally advanced leiomyosarcoma of the spleen. A case report and review of the literature","volume":"5","author":"Piovanello P","year":"2007","unstructured":"Piovanello P, Viola V, Costa G, et al.. Locally advanced leiomyosarcoma of the spleen. A case report and review of the literature. World J Surg Oncol. 2007, 5:135. 10.1186\/1477-7819-5-135","journal-title":"World J Surg Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.111706","article-title":"Leiomyosarcoma of the spleen","volume":"130","author":"Daudia AT","year":"2001","unstructured":"Daudia AT, Walker S, Morgan B, Lloyd DM. Leiomyosarcoma of the spleen. Surgery. 2001, 130:893-4. 10.1067\/msy.2001.111706","journal-title":"Surgery"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki RG","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, et al.. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007, 25:2755-63. 10.1200\/JCO.2006.10.4117","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley ML","year":"2008","unstructured":"Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008, 109:329-34. 10.1016\/j.ygyno.2008.03.010","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon B","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, et al.. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017, 18:1397-410. 10.1016\/S1470-2045(17)30622-8","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf WTA","year":"2012","unstructured":"van der Graaf WTA, Blay JY, Chawla SP, et al.. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012, 379:1879-86. 10.1016\/S0140-6736(12)60651-5","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465988-durable-disease-control-in-disseminated-primary-splenic-leiomyosarcoma-treated-with-sequential-gemcitabine-docetaxel-and-pazopanib-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:59:14Z","timestamp":1775530754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465988-durable-disease-control-in-disseminated-primary-splenic-leiomyosarcoma-treated-with-sequential-gemcitabine-docetaxel-and-pazopanib-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.106553","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}